"use strict";(self.webpackChunkgatsby_starter_default=self.webpackChunkgatsby_starter_default||[]).push([[567],{5786:function(t,l,n){n.r(l),n.d(l,{_frontmatter:function(){return u},default:function(){return s}});var e=n(3366),i=(n(7294),n(4983)),a=n(5887),r=["components"],u={},o={_frontmatter:u},k=a.Z;function s(t){var l=t.components,n=(0,e.Z)(t,r);return(0,i.kt)(k,Object.assign({},o,n,{components:l,mdxType:"MDXLayout"}),(0,i.kt)("h1",null,"Molecular profiling for precision cancer therapies (2020)"),(0,i.kt)("h2",null,"Overview"),(0,i.kt)("ol",null,(0,i.kt)("li",{parentName:"ol"},"describe novel molecular characterization strategies beyond tumor DNA sequencing",(0,i.kt)("ul",{parentName:"li"},(0,i.kt)("li",{parentName:"ul"},"transcriptomics"),(0,i.kt)("li",{parentName:"ul"},"immunophenotyping"),(0,i.kt)("li",{parentName:"ul"},"epigenetic profiling"),(0,i.kt)("li",{parentName:"ul"},"single-cell analyses"))),(0,i.kt)("li",{parentName:"ol"},"review current and potential applications of liquid biopsies to evaluate blood-based biomarkers such as circulating tumor cells and circulating nucleic acids"),(0,i.kt)("li",{parentName:"ol"},"lessons learned from the existing limitations of genotype-derived therapies  and ways to expand precision medicine beyond genomics")),(0,i.kt)("h2",null,"FDA/EMA approved biomarkers and matching targeted drugs"),(0,i.kt)("table",null,(0,i.kt)("thead",null,(0,i.kt)("tr",null,(0,i.kt)("th",null,"Gene/protein"),(0,i.kt)("th",null,"Anticancer agent"),(0,i.kt)("th",null,"Indications"),(0,i.kt)("th",null,"Biomarker"),(0,i.kt)("th",null,"Routine testing"))),(0,i.kt)("tbody",null,(0,i.kt)("tr",null,(0,i.kt)("td",null,"ALK"),(0,i.kt)("td",null,"Crizotinib, ceritinib, alectinib, lorlatinib, brigatinib"),(0,i.kt)("td",null,"NSCLC"),(0,i.kt)("td",null,"ALK translocation"),(0,i.kt)("td",null,"FISH, IHC")),(0,i.kt)("tr",null,(0,i.kt)("td",null,"Androgen receptor (AR)"),(0,i.kt)("td",null,"Abiraterone, enzalutamide, dalurotamide, apalutamide"),(0,i.kt)("td",null,"Prostate cancer"),(0,i.kt)("td",null,"AR expression"),(0,i.kt)("td",null,"IHC")),(0,i.kt)("tr",null,(0,i.kt)("td",null,"BCL-2"),(0,i.kt)("td",null,"Venetoclax"),(0,i.kt)("td",null,"Chronic myeloid leukemia"),(0,i.kt)("td",null,"BCL-2 protein expression, BCL-2 amplification/translocation"),(0,i.kt)("td",null,"IHC, FISH")),(0,i.kt)("tr",null,(0,i.kt)("td",null,"BCR/ABL"),(0,i.kt)("td",null,"Imatinib, dasatinib, nilotinib, bosutinib, ponatinib"),(0,i.kt)("td",null,"Chronic myeloid leukemia"),(0,i.kt)("td",null,"BCR/ABL1 fusion"),(0,i.kt)("td",null,"IHC (FISH, DNA/RNA sequencing), PCR1")),(0,i.kt)("tr",null,(0,i.kt)("td",null,"BRAF"),(0,i.kt)("td",null,"Dabrafenib+trametinib, vemurafenib+cobimetinib, encorafenib+binimetinib"),(0,i.kt)("td",null,"Melanoma, NSCLC, anaplastic thyroid cancer, hairy cell leukemia"),(0,i.kt)("td",null,"BRAF V600E/K mutations"),(0,i.kt)("td",null,"IHC, PCR1, DNA sequencing")),(0,i.kt)("tr",null,(0,i.kt)("td",null,"BRCA"),(0,i.kt)("td",null,"Olaparib, talazoparib, rucaparib"),(0,i.kt)("td",null,"Breast cancer, ovarian cancer"),(0,i.kt)("td",null,"Germline/somatic BRCA 1/2 mutations"),(0,i.kt)("td",null,"DNA sequencing")),(0,i.kt)("tr",null,(0,i.kt)("td",null,"C-KIT, PDGFR"),(0,i.kt)("td",null,"Imatinib"),(0,i.kt)("td",null,"Gastrointestinal stromal tumor"),(0,i.kt)("td",null,"c-KIT Exon 9 and 11 mutations, PDGFR mutations"),(0,i.kt)("td",null,"IHC, DNA sequencing")),(0,i.kt)("tr",null,(0,i.kt)("td",null,"PDGFRB"),(0,i.kt)("td",null,"Imatinib"),(0,i.kt)("td",null,"Myelodysplastic/myeloproliferative syndromes"),(0,i.kt)("td",null,"PDGFRB rearrangement"),(0,i.kt)("td",null,"FISH")),(0,i.kt)("tr",null,(0,i.kt)("td",null,"Estrogen/progesterone receptors (ER/PR)"),(0,i.kt)("td",null,"Tamoxifen, raloxifene, fulvestrant, toremifine"),(0,i.kt)("td",null,"Breast cancer"),(0,i.kt)("td",null,"ER/PR expression"),(0,i.kt)("td",null,"IHC")),(0,i.kt)("tr",null,(0,i.kt)("td",null,"erBB2/HER-2"),(0,i.kt)("td",null,"Trastuzumab, pertuzumab, ado-trastuzumab, emtansine, neratinib"),(0,i.kt)("td",null,"Breast cancer, gastric cancer"),(0,i.kt)("td",null,"HER-2 protein expression, HER-2 amplification"),(0,i.kt)("td",null,"IHC, FISH")),(0,i.kt)("tr",null,(0,i.kt)("td",{rowSpan:"2"},"EGFR"),(0,i.kt)("td",null,"Gefitinib, erlotinib, afatinib, dacomitinib"),(0,i.kt)("td",{rowSpan:"2"},"NSCLC"),(0,i.kt)("td",null,"EGFR exon 19 deletion, exon 21 L858R mutation"),(0,i.kt)("td",{rowSpan:"2"},"DNA sequencing, PCR1")),(0,i.kt)("tr",null,(0,i.kt)("td",null,"Osimertinib"),(0,i.kt)("td",null,"EGFR T790M mutation")),(0,i.kt)("tr",null,(0,i.kt)("td",null,"FGFR2/3"),(0,i.kt)("td",null,"Erdafitinib"),(0,i.kt)("td",null,"Bladder cancer"),(0,i.kt)("td",null,"FGFR3 mutations, FGFR2/3 fusions"),(0,i.kt)("td",null,"DNA sequencing, FISH")),(0,i.kt)("tr",null,(0,i.kt)("td",null,"FLT3"),(0,i.kt)("td",null,"Midostaurin, gilteritinib"),(0,i.kt)("td",null,"Acute myeloid leukemia"),(0,i.kt)("td",null,"FLT3 mutations"),(0,i.kt)("td",null,"DNA sequencing, PCR1")),(0,i.kt)("tr",null,(0,i.kt)("td",null,"IDH1/2"),(0,i.kt)("td",null,"Ivosidenib, enasidenib"),(0,i.kt)("td",null,"Acute myeloid leukemia"),(0,i.kt)("td",null,"IDH1/2 mutations"),(0,i.kt)("td",null,"IHC, DNA sequencing")),(0,i.kt)("tr",null,(0,i.kt)("td",null,"MET"),(0,i.kt)("td",null,"Crizotinib (breakthrough designation)"),(0,i.kt)("td",null,"NSCLC"),(0,i.kt)("td",null,"MET amplification, MET exon 14 alterations"),(0,i.kt)("td",null,"FISH, DNA/RNA sequencing")),(0,i.kt)("tr",null,(0,i.kt)("td",{rowSpan:"2"},"MSI-H or dMMR"),(0,i.kt)("td",null,"Pembrolizumab"),(0,i.kt)("td",null,"MSI-H or dMMR solid tumors"),(0,i.kt)("td",{rowSpan:"2"},"MLH1, MSH2, MSH6, PMS2 protein expression, MSI high"),(0,i.kt)("td",{rowSpan:"2"},"IHC, DNA sequencing, PCR1")),(0,i.kt)("tr",null,(0,i.kt)("td",null,"Nivolumab and ipilimumab"),(0,i.kt)("td",null,"Colorectal cancer")),(0,i.kt)("tr",null,(0,i.kt)("td",null,"NTRK"),(0,i.kt)("td",null,"Larotrectinib, entrectinib"),(0,i.kt)("td",null,"Solid tumors with NTRK fusions"),(0,i.kt)("td",null,"NTRK protein expression, NTRK fusion"),(0,i.kt)("td",null,"IHC, FISH, DNA/RNA sequencing")),(0,i.kt)("tr",null,(0,i.kt)("td",null,"PI3KCA"),(0,i.kt)("td",null,"Alpelisib"),(0,i.kt)("td",null,"Breast cancer"),(0,i.kt)("td",null,"PI3KCA mutation"),(0,i.kt)("td",null,"DNA sequencing")),(0,i.kt)("tr",null,(0,i.kt)("td",null,"PI3K (alpha and delta)"),(0,i.kt)("td",null,"Copanlisib"),(0,i.kt)("td",null,"Follicular lymphoma"),(0,i.kt)("td",null,"PI3K mutation"),(0,i.kt)("td",null,"DNA sequencing")),(0,i.kt)("tr",null,(0,i.kt)("td",null,"PI3K (delta and gamma)"),(0,i.kt)("td",null,"Duvelisib"),(0,i.kt)("td",null,"Chronic lymphocytic leukemia, small lymphocytic lymphoma"),(0,i.kt)("td",null,"PI3K mutation"),(0,i.kt)("td",null,"DNA sequencing")),(0,i.kt)("tr",null,(0,i.kt)("td",null,"RAS (negative predictor)"),(0,i.kt)("td",null,"Cetuximab, panitumumab"),(0,i.kt)("td",null,"Colorectal cancer"),(0,i.kt)("td",null,"KRAS/NRAS wildtype"),(0,i.kt)("td",null,"DNA sequencing")),(0,i.kt)("tr",null,(0,i.kt)("td",null,"RET"),(0,i.kt)("td",null,"LOXO-292 (breakthrough designation)"),(0,i.kt)("td",null,"NSCLC, medullary thyroid cancer"),(0,i.kt)("td",null,"RET fusion, RET mutation"),(0,i.kt)("td",null,"FISH, DNA/RNA sequencing")),(0,i.kt)("tr",null,(0,i.kt)("td",null,"ROS1"),(0,i.kt)("td",null,"Crizotinib, entrectinib"),(0,i.kt)("td",null,"NSCLC"),(0,i.kt)("td",null,"ROS translocation"),(0,i.kt)("td",null,"FISH, DNA/RNA sequencing")))),(0,i.kt)("h2",null,"Current and emerging molecular approaches to enable precision medicine"),(0,i.kt)("ul",null,(0,i.kt)("li",{parentName:"ul"},"conventional tests",(0,i.kt)("ul",{parentName:"li"},(0,i.kt)("li",{parentName:"ul"},"immunohistochemistry (IHC)"),(0,i.kt)("li",{parentName:"ul"},"fluorescence in situ hybridization (FISH)",(0,i.kt)("ul",{parentName:"li"},(0,i.kt)("li",{parentName:"ul"},"gold standard for detecting DNA rearrangements"))))),(0,i.kt)("li",{parentName:"ul"},"NGS tests")),(0,i.kt)("h3",null,"NGS: Targeted gene panels vs. whole exome vs. whole genome sequencing"),(0,i.kt)("ul",null,(0,i.kt)("li",{parentName:"ul"},"targeted gene panels (currently) preferred in clinical settings",(0,i.kt)("ul",{parentName:"li"},(0,i.kt)("li",{parentName:"ul"},"better depth of coverage"),(0,i.kt)("li",{parentName:"ul"},"faster turnaround"),(0,i.kt)("li",{parentName:"ul"},"more clinically relevant data"))),(0,i.kt)("li",{parentName:"ul"},"setbacks",(0,i.kt)("ul",{parentName:"li"},(0,i.kt)("li",{parentName:"ul"},(0,i.kt)("strong",{parentName:"li"},"driver")," vs. ",(0,i.kt)("strong",{parentName:"li"},"passenger")," mutations")))),(0,i.kt)("h3",null,"Liquid biopsies"),(0,i.kt)("ul",null,(0,i.kt)("li",{parentName:"ul"},"blood, urine, peritoneal fluid, cerebrospinal fluid"),(0,i.kt)("li",{parentName:"ul"},"look for",(0,i.kt)("ul",{parentName:"li"},(0,i.kt)("li",{parentName:"ul"},"CTCs"),(0,i.kt)("li",{parentName:"ul"},"ctDNA"),(0,i.kt)("li",{parentName:"ul"},"RNA"),(0,i.kt)("li",{parentName:"ul"},"protein"),(0,i.kt)("li",{parentName:"ul"},"metabolites"))),(0,i.kt)("li",{parentName:"ul"},"clinical uses",(0,i.kt)("ul",{parentName:"li"},(0,i.kt)("li",{parentName:"ul"},"monitoring persistence of radiological undetectable tumors"),(0,i.kt)("li",{parentName:"ul"},"prediction of recurrence"),(0,i.kt)("li",{parentName:"ul"},"monitoring of treatment response"),(0,i.kt)("li",{parentName:"ul"},"early detection of resistance mechanisms"),(0,i.kt)("li",{parentName:"ul"},"assessment of tumor burden"),(0,i.kt)("li",{parentName:"ul"},"tracking clonal evolution of tumors"),(0,i.kt)("li",{parentName:"ul"},"dynamic evaluation of immune biomarkers such as PD-L1 expression and tumor mutation burden")))),(0,i.kt)("h3",null,"Single cell analysis"),(0,i.kt)("ul",null,(0,i.kt)("li",{parentName:"ul"},"single-cell analysis of CTC",(0,i.kt)("ul",{parentName:"li"},(0,i.kt)("li",{parentName:"ul"},"multi-omic assessment"),(0,i.kt)("li",{parentName:"ul"},"generation of patient-specific tumor models (organoids and xenografts)"),(0,i.kt)("li",{parentName:"ul"},"viable CTCs are implicated in metastasis, may detect actionable aberrations")))),(0,i.kt)("h3",null,"Nascent biomarkers"),(0,i.kt)("ul",null,(0,i.kt)("li",{parentName:"ul"},"circulating-free miRNA",(0,i.kt)("ul",{parentName:"li"},(0,i.kt)("li",{parentName:"ul"},"need for standardized collection techniques in order for tests to be clinically useful")))),(0,i.kt)("h2",null,"Taking actions on genomic results"),(0,i.kt)("ul",null,(0,i.kt)("li",{parentName:"ul"},"databases with pre-clinical biological and functional data",(0,i.kt)("ul",{parentName:"li"},(0,i.kt)("li",{parentName:"ul"},"TCGA"),(0,i.kt)("li",{parentName:"ul"},"International Cancer Genome Consortium (ICGC)"))),(0,i.kt)("li",{parentName:"ul"},"databases with most updated evidence on the clinical benefit obtained from matched drugs that can be used to drive variant-specific treatment recommendations",(0,i.kt)("ul",{parentName:"li"},(0,i.kt)("li",{parentName:"ul"},"OncoKB"),(0,i.kt)("li",{parentName:"ul"},"MyCancerGenome"),(0,i.kt)("li",{parentName:"ul"},"CIViC"))),(0,i.kt)("li",{parentName:"ul"},'Shift towards "pan-cancer" biomarker indications for therapeutics')),(0,i.kt)("h2",null,"Ways to expand precision medicine"),(0,i.kt)("ul",null,(0,i.kt)("li",{parentName:"ul"},"Transcriptomics increases actionability, but efficacy of therapies stayed the same: 20 to 30%.")),(0,i.kt)("h3",null,"Current limitations"),(0,i.kt)("ul",null,(0,i.kt)("li",{parentName:"ul"},"lack of clinical trial availability"),(0,i.kt)("li",{parentName:"ul"},"cost of targeted drugs")),(0,i.kt)("h3",null,"Current directions"),(0,i.kt)("ul",null,(0,i.kt)("li",{parentName:"ul"},"increased trial opportunities",(0,i.kt)("ul",{parentName:"li"},(0,i.kt)("li",{parentName:"ul"},'more flexible trial structure with "master protocols" that can be tuned per patient')))))}s.isMDXComponent=!0},5819:function(t,l,n){n.d(l,{Z:function(){return i}});var e=n(7294),i=function(t){var l=t.children;return e.createElement("div",{className:"layout-module--layoutContainer--cHTez"},l)}},5887:function(t,l,n){n.d(l,{Z:function(){return k}});var e={};n.r(e);var i=n(7294),a=n(4983),r=n(5444),u=n(5819);n(749);var o={Link:r.rU,RA:function(){return i.createElement("span",null,"⇒")}},k=function(t){var l=t.children;return i.createElement(u.Z,null,i.createElement("div",{className:e.summaryContainer},i.createElement(a.Zo,{components:o},l)))}},749:function(t,l,n){n.r(l)},3366:function(t,l,n){function e(t,l){if(null==t)return{};var n,e,i={},a=Object.keys(t);for(e=0;e<a.length;e++)n=a[e],l.indexOf(n)>=0||(i[n]=t[n]);return i}n.d(l,{Z:function(){return e}})}}]);
//# sourceMappingURL=component---src-pages-papers-s-13073-019-0703-1-index-mdx-f94d3198650334f0ea04.js.map